Loading company…
Tribune Therapeutics develops medicines for fibrotic diseases, including liver, kidney, and lung fibrosis.
Founded in 2020 and based in Stockholm, Sweden, Tribune Therapeutics is a preclinical biopharmaceutical company developing medicines for fibrotic diseases. Its lead candidate, TRX-44, targets CCN signaling to block fibrotic signaling and scar tissue formation. In March 2025, LifeArc led an undisclosed Series A round, with Industrifonden, Investinor, HealthCap, Innovestor, Inven2, and Novo Holdings participating. The company planned to prepare clinical trials for its lead program and advance other programs targeting the protein family.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in